Skip to main content

Table 1 Additional treatments

From: Treatment of Branch Retinal Vein Occlusion induced Macular Edema with Bevacizumab

Patient

Time-to-Treat [d]

Visual Gain

Follow-up [d]

Total Injections

Focal Laser [m]

Hemodilution

Intravitreal Triamcinolone [m]

Other

1

2232

0.0

119

1

-

-

-

-

2

59

0.8

57

1

-

-

-

-

3

19

0.2

341

4

-

y

-

-

4

77

0.2

172

2

-

-

-

-

5

6715

0.3

94

1

-1

-

-

-

6

17

1.1

221

3

+4,+13

-

-

-

7

37

0.7

250

3

-

-

-

-

8

211

0.2

109

1

-

-

-

-

9

6

0.0

91

1

-

-

-

-

10

1041

0.1

193

2

-

-

-

-

11

26

-0.1

33

1

-

-

-

-

12

505

0.0

90

1

-14,-12,-9,-8,-3,-2

-

-14, +2

-

13

9

0.0

278

2

+1,+2,+8,+12

-

+9

-

14

456

0.6

236

2

+1,+2,+3,+7

-

-15

-

15

973

0.1

57

1

-27,-24

-

-

-

16

598

0.2

27

1

-8,-3

-

-3

-

17

134

0.3

418

1

-3,-2,+13

-

-

-

18

10

0.6

179

2

-

-

-

-

19

216

0.1

339

2

+1

-

-

-

20

5

-0.2

171

2

+1,+4,+6

-

-

-

21

1794

0.3

284

4

+1

-

-

-

22

5

0.3

38

1

-

-

-

-

23

64

0.2

48

1

-

y

-

-

24

254

0.1

234

4

+2,+7

-

-

-

25

626

0.1

31

1

-

-

-

-

26

5

-0.2

168

2

-

-

-

-

27

47

0.6

229

3

+6,+7,+11

-

-

-

28

92

-0.3

28

1

-3

-

-

-

29

854

0.0

81

1

-

-

-

vitrectomy at +2 m for tractive retinal detachment

30

312

0.1

360

2

-2,+7

-

-

vitrectomy at +7 m for vitreous hemorrhage

31

8

0.1

96

1

-

-

-

-

32

371

0.0

175

1

-

-

-

-

  1. Patients were treated prior and/or after initiation of Bevacizumab treatment with focal laser or intravitreal triamcinolone. Hemodilution was made within the first weeks of diagnosis. No additional treatment was applied between the first injection and the subsequent visit 4 to 6 weeks later. Time points are represented in months (m) or days (d) prior to (negative values) or after (positive values) the first Bevacizumab injection.